From cutting edge science to the impact of Obamacare, from clinical trial results to FDA decisions, and from Bieber fever to hay fever, The Motley Fool's health-care team sits down each week to discuss the most fascinating developments across the health-care industry and their implications for long-term investors. In this week's edition, the team talks about an exciting drug approval, how computers can help scientists develop new drugs, and stocks that have both soared and crashed. The analysts close with a discussion of companies they will be closely following in the coming weeks.
In the segment below, health-care analyst Max Macaluso discusses Valeant Pharmaceuticals' recent acquisition of skin care specialist Obagi Medical Products .
What macro trend was Warren Buffett referring to when he said, "This is the tapeworm that's eating at American competitiveness?" Find out in our free report, What's Really Eating At America's Competitiveness. You'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.
The relevant video segment can be found between 10:14 and 11:26.
The article Was Obagi Medical the Right Acquisition for Valeant? originally appeared on Fool.com.
Brenton Flynn has no position in any stocks mentioned. David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.